Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: The SMOOTH study

Cardiovascular Diabetology

Volumn 6, Issue , 2007, Pages

  Sharma, Arya M ^a   Davidson, Jaime ^b   Koval, Stephen ^c   Lacourcière, Yves ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b Endocrine and Diabetes Associates of Texas   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POTASSIUM; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DRUG DERIVATIVE; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE; VALINE;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADULT; AGED; AMBULATORY MONITORING; ANKLE FRACTURE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BIPOLAR DISORDER; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; GASTROESOPHAGEAL REFLUX; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; INTRACRANIAL ANEURYSM; JOINT DISLOCATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; BLOOD PRESSURE; DIASTOLE; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; SYSTOLE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES MELLITUS, TYPE 2; DIASTOLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; OBESITY; PLACEBOS; SINGLE-BLIND METHOD; SYSTOLE; TETRAZOLES; VALINE;

EID: 36349011426     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-6-28     Document Type: Article

References (32)

1. Rahmouni K Correia ML Haynes WG Mark AL Obesity-associated hypertension: new insights into mechanisms Hypertension 2005, 45:9-14. 10.1161/ 01.HYP.0000154312.87612.07 15583075
2. Sharma AM Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004, 44:12-19. 10.1161/ 01.HYP.0000132568.71409.a2 15173127
3. Bramlage P Pittrow D Wittchen HU Kirch W Boehler S Lehnert H Hoefler M Unger T Sharma AM Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled Am J Hypertens 2004, 17:904-910. 10.1016/j.amjhyper.2004.05.017 15485752
4. Marler JR Price TR Clark GL Muller JE Robertson T Mohr JP Hier DB Wolf PA Caplan LR Foulkes MA Morning increase in onset of ischemic stroke Stroke 1989, 20:473-476. 2648651
5. Kario K Time for focus on morning hypertension: Pitfall of current antihypertensive medication Am J Hypertens 2005, 18:149-151. 10.1016/ j.amjhyper.2004.09.007 15752939
6. Burnier M Maillard M The comparative pharmacology of angiotensin II receptor antagonists Blood Press Suppl 2001, 1:6-11. 11333013
7. Kakuta H Sudoh K Sasmata M Yamagishi S Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers Int J Clin Pharmacol Res 2005, 25(1):41-46. 15864875
8. Wienen W Entzeroth M van Meel JCA Stangier J Busch U Ebner T Schmid J Lehmann H Matzek K Kempthorne-Rawson J Gladigau V Hauel HH A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist Cardiovasc Drug Rev 2002, 18:127-156.
9. Gosse P Neutel JM Schumacher H Lacourcière Y Williams B Davidai G The effect of telmisartan and ramipril on early morning blood pressure surge: A pooled analysis of two randomized clinical trials Blood Press Monit 2007, 12:141-147. 10.1097/MBP.0b013e3280b10bbd 17496463
10. Fogari R Derosa G Zoppi A Rinaldi A Lazzari P Fogari E Mugellini A Preti P Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients Hypertens Res 2005, 28:209-214. 10.1291/hypres.28.209 16097363
11. Lacourcière Y Krzesinski JM White WB Davidai G Schumacher H Sustained antihypertensive activity of telmisartan compared with valsartan Blood Press Monit 2004, 9:203-210. 10.1097/ 00126097-200408000-00005 15311147
12. White WB Punzi HA Murwin D Koval SE Davidai G Neutel JM Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension J Clin Hypertens (Greenwich) 2006, 8(9):626-633. 10.1111/ j.1524-6175.2006.05411.x 16957424
13. White WB Guthrie R Chrysant SG Murwin D Davidai G Koval S A second large trial of Telmisartan and HCTZ (80/25 mg) shows a larger antihypertensive effect than Valsartan and HCTZ (160/25 mg) J Clin Hypertens 2007, 9(Suppl A):A44 (Abstract P-94)
14. Smith DH Neutel JM Lacourcière Y Kempthorne-Rawson J Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements J Hypertens 2003, 21:1291-1298. 10.1097/ 00004872-200307000-00016 12817175
15. American Diabetes Association Treatment of hypertension in adults with diabetes Diabet Care 2002, 25:199-201. 10.2337/diacare.25.1.199
16. Chobanian AV Bakris GL Black HR Cushman WC Green LA Izzo JL Jr Jones DW Materson BJ Oparil S Wright JT Jr Roccella EJ The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 2003, 289:2560-2572. 10.1001/ jama.289.19.2560 12748199
17. Sharma AM Bramlage P Kirch W Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: A prospective, open-label study Clin Drug Investig 2005, 25:765-776. 10.2165/00044011-200525120-00003 17532722
18. Jordan J Engeli S Boschmann M Weidinger G Luft FC Sharma AM Kreuzberg U Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients J Hypertens 2005, 23:2313-2318. 10.1097/ 01.hjh.0000188734.98463.82 16269974
19. Grassi G Seravalle G Dell'Oro R Trevano FQ Bombelli M Scopelliti F Facchini A Mancia G Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results from the CROSS study J Hypertens 2003, 21:1761-1769. 10.1097/ 00004872-200309000-00027 12923410
20. Bangalore S Shahane A Parkar S Messerli FH Compliance and fixed-dose combination therapy Curr Hypertens Rep 2007, 9:184-189. 10.1007/ s11906-007-0033-3 17519122
21. Lacourcière Y Neutel JM Davidai G Koval S A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring Am J Hypertens 2006, 19:104-112. 10.1016/j.amjhyper.2005.10.001 16461201
22. Poirier L de Champlain J Larochelle P Lamarre-Cliche M Lacourciere Y A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension Blood Press Monit 2004, 9:231-236. 10.1097/ 00126097-200410000-00001 15472494
23. Williams B Gosse P Lowe L Harper R on behalf of the PRISMA I Study Group The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I) J Hypertens 2006, 24:193-200. 16331118
24. Lacourcière Y Neutel JM Schumacher H Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: Pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials Clin Ther 2005, 27:1795-1805. 10.1016/ j.clinthera.2005.11.014 16368450
25. Smith DH Cramer MJ Neutel JM Hettiarachchi R Koval S Comparison of telmisartan versus losartan: Meta-analysis of titration-to-response studies Blood Press Monit 2003, 8:111-117. 12900588
26. Neldam S Edwards C ATHOS Study Group Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study Am J Geriatr Cardiol 2006, 15:151-160. 10.1111/j.1076-7460.2006.05219.x 16687967
27. EllioCt HL Meredith PA Trough:pEak ratio: clinically useful or practically irrelevant? J Hypertens 1995, 13:279-283. 10.1097/ 00004872-199503000-00001 7622847
28. Stangier J Su CAPF Roth W Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients J Int Med Res 2000, 28:149-167. 11014323
29. Lewington S Clarke R Qizilbash N Peto R Collins R Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies Lancet 2002, 360:1903-1913. 10.1016/S0140-6736(02)11911-8 12493255
30. Suzuki H Kanno Y Nakamoto H Okada H Sugahara S Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy Clin Exp Hypertens 2005, 27:129-138. 10.1081/CEH-200048735 15835375
31. Elliott WJ Cyclic and circadian variations in cardiovascular events Am J Hypertens 2001, 14:291S-295S. 10.1016/S0895-7061(01)02174-4 11583142
32. Sharma AM Davidson JA Gavin JR III DeSousa NJ Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes Hypertension 2005, 46:898-899.